LIPOMATRIX TRIGLYCERIDE-FILLED BREAST IMPLANT U.S. CLINICALS TO BEGIN
This article was originally published in The Gray Sheet
Executive SummaryLIPOMATRIX TRIGLYCERIDE-FILLED BREAST IMPLANT U.S. CLINICALS TO BEGIN in September under an investigational device exemption approved by FDA July 15. LipoMatrix will be seeking a maximum of 50 patients "with older, but problematic implants" to take part in a five-center pilot trial studying the company's Trilucent breast implant as a replacement device.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.